Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China

Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China

Abstract Background Cell-free fetal DNA (cffDNA) has opened up new approaches for non-invasive prenatal testing (NIPT), and it is often used as the second-tier test for high-risk pregnant women in detecting trisomy (T) 21, T18, and T13 after serum biochemistry screening. This study aims to discuss t...

Full description

Bibliographic Details
Main Authors: Yanhui Liu, Hailiang Liu, Yi He, Wanfang Xu, Qiulin Ma, Yuzhen He, Wei Lei, Guoquan Chen, Zheng He, Jiayi Huang, Jianan Liu, Yuanru Liu, Quanfei Huang, Fubing Yu
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Human Genomics
Subjects:
Non-invasive prenatal testing (NIPT)
First-tier screening test
Positive predictive value (PPV)
Sex chromosome aneuploidy
Advanced maternal age (AMA)
Online Access:http://link.springer.com/article/10.1186/s40246-020-00268-2

Internet

http://link.springer.com/article/10.1186/s40246-020-00268-2

Similar Items